# Lactococcus lactis subsp. lactis biovar diacetylactis DRC1

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactococcus-lactis-subsp-lactis-biovar-diacetylactis-drc1
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Lactococcus lactis subsp. lactis biovar diacetylactis DRC1, L. lactis DRC1, Lactococcus lactis DRC1, DRC1 strain, Diacetylactis DRC1, Lactic acid bacterium DRC1

## Overview

Lactococcus lactis subsp. lactis biovar diacetylactis DRC1 is a lactic acid bacterium that produces diacetyl, nisin-related bacteriocins, and [immunomodulatory](/ingredients/condition/immune-support) cell wall components including peptidoglycans and lipoteichoic acids. Its primary mechanisms involve stimulating innate immune pathways via Toll-like receptor 2 activation and competitive exclusion of pathogens through lactic acid and bacteriocin production.

## Health Benefits

• May enhance immune response in cancer therapy (preliminary evidence from 3-patient observation with engineered variant)
• Potential wound healing properties (animal studies show mixed results with high-dose administration)
• Disease resistance enhancement in aquaculture (shrimp survival improved to 79.2% in challenge studies)
• Microbiota modulation and [digestive enzyme](/ingredients/condition/gut-health) enhancement (based on general L. lactis probiotic mechanisms)
• Selective tumor cell targeting without normal cell toxicity (engineered variants in preclinical studies)

## Mechanism of Action

DRC1 produces diacetyl and lactic acid, lowering local pH to inhibit competing pathogens, while cell wall-derived lipoteichoic acids and peptidoglycans engage Toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain (NOD) receptors to stimulate NF-κB-mediated [cytokine](/ingredients/condition/inflammation) release including IL-6, IL-12, and TNF-α. Engineered variants have been designed to express immunostimulatory proteins, potentially enhancing antigen presentation via MHC class II pathways in dendritic cells. Additionally, bacteriocin-like inhibitory substances (BLIS) produced by DRC1 disrupt target bacterial membrane integrity through pore formation, contributing to its [antimicrobial](/ingredients/condition/immune-support) activity.

## Clinical Summary

Human clinical evidence for DRC1 specifically is extremely limited, with the most notable data coming from a preliminary 3-patient observational report examining an engineered DRC1 variant in the context of cancer immunotherapy adjunction, producing no statistically generalizable conclusions. Animal studies, particularly in murine wound-healing models, have shown mixed results, with high-dose topical administration demonstrating variable tissue regeneration outcomes depending on wound type and delivery vehicle. Aquaculture research provides the most consistent positive data, with shrimp survival rates showing measurable improvement in Vibrio-challenge models following DRC1 supplementation in feed, though study sizes and methodologies vary considerably. Overall, the evidence base remains preclinical and preliminary, and no randomized controlled human trials have been published for this specific biovar.

## Nutritional Profile

Lactococcus lactis subsp. lactis biovar diacetylactis DRC1 is a lactic acid bacterium whose direct macronutrient contribution as a food ingredient is minimal given typical probiotic administration doses (10^6–10^9 CFU/serving). As a bacterial cell mass, it contains approximately 50–60% protein (dry weight basis), 15–25% carbohydrates (primarily cell wall polysaccharides and peptidoglycans), and 10–20% lipids (largely membrane phospholipids and glycolipids). Key bioactive compounds include: diacetyl (characteristic metabolite of this biovar, produced via citrate [metabolism](/ingredients/condition/weight-management), contributing aroma and antimicrobial properties at concentrations of 1–5 mg/L in fermented media); nisin A or nisin Z (bacteriocin produced by many L. lactis strains, typically 100–1000 IU/mL in fermentation; antimicrobial peptide targeting Gram-positive pathogens); exopolysaccharides (EPS, 50–200 mg/L range in culture, contributing [prebiotic](/ingredients/condition/gut-health)-like and [immunomodulatory](/ingredients/condition/immune-support) activity); lactic acid (primary fermentation end product, 0.5–1.5% w/v in fermented matrices, contributing acidification and preservation); acetoin and acetaldehyde (secondary metabolites from diacetyl pathway). Micronutrient contributions include B-vitamins synthesized during fermentation, notably riboflavin (B2, ~0.5–2.0 µg/mL), folate (B9, ~50–150 ng/mL in fermented product), and cobalamin (B12 trace amounts, strain-dependent). Cell wall components including peptidoglycan fragments and lipoteichoic acids serve as pattern recognition ligands (PAMPs) with documented immunostimulatory activity via TLR2 signaling. Bioavailability is context-dependent: viable cells transiting the GI tract show partial survival through gastric acid (pH tolerance to ~4.0) and bile salts; metabolites such as lactic acid and diacetyl are bioavailable systemically; EPS and cell wall fragments interact primarily at mucosal surfaces. Data specific to DRC1 strain nutritional output beyond biovar-class characterization remains limited in published literature.

## Dosage & Preparation

Animal studies used 10^8 CFU/g in feed for disease resistance and 1×10^11 CFU/ml for wound healing models. Human phase I trials used dose-escalation of recombinant L. lactis (exact CFU unspecified). No standardized human dosage for DRC1 strain specifically established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

DRC1 is generally regarded as safe under GRAS principles applicable to food-grade Lactococcus lactis strains, with no significant adverse effects reported in animal studies at standard doses. Individuals who are severely immunocompromised, including those on high-dose corticosteroids, calcineurin inhibitors, or biologics targeting TNF-α or IL-6, should exercise caution, as immune stimulation could theoretically interact with these pathways. No documented drug-drug interactions specific to DRC1 exist in the published literature, though concurrent use with broad-spectrum antibiotics may reduce bacterial viability and diminish [probiotic](/ingredients/condition/gut-health) effects. Pregnancy and lactation safety has not been formally studied for this specific biovar; standard food-grade Lactococcus lactis is considered low-risk in food contexts, but supplemental use during pregnancy should be discussed with a healthcare provider.

## Scientific Research

Limited human clinical evidence exists specifically for DRC1; a phase I dose-escalation trial (PMID: 31645442) with related L. lactis strains in healthy Iranian women showed no adverse events. Most evidence comes from preclinical studies including a 3-patient observation using engineered FOLactis with radiotherapy and animal models demonstrating wound healing and disease resistance effects.

## Historical & Cultural Context

L. lactis subsp. lactis biovar diacetylactis has no documented historical use in traditional medicine systems, being primarily known from modern dairy fermentation rather than ancient herbal practices. Recent ethnopharmacological evaluation includes strains from dadih (fermented buffalo milk), but this represents contemporary research rather than long-term traditional use.

## Synergistic Combinations

Other Lactococcus strains, Bifidobacterium species, Lactobacillus acidophilus, [Prebiotic](/ingredients/condition/gut-health) fibers, Saccharomyces boulardii

## Frequently Asked Questions

### What makes Lactococcus lactis biovar diacetylactis DRC1 different from regular Lactococcus lactis?

The 'diacetylactis' biovar designation specifically indicates DRC1 possesses the genetic machinery to metabolize citrate and produce diacetyl, the compound responsible for a buttery aroma, via citrate lyase and alpha-acetolactate synthase pathways. This metabolic capability distinguishes it from standard L. lactis subsp. lactis strains and may contribute to additional antimicrobial activity through diacetyl's membrane-disrupting properties at sufficient concentrations. The DRC1 designation further identifies it as a specific strain with characterized immune-modulating and aquaculture-relevant properties.

### Can Lactococcus lactis DRC1 help with immune function in cancer patients?

The only available human data comes from a 3-patient preliminary observation involving an engineered DRC1 variant used alongside cancer therapy, which is insufficient to draw any clinical conclusions about efficacy or safety in oncology contexts. The theoretical basis involves DRC1's ability to stimulate TLR2 and NF-κB pathways, potentially enhancing innate immune surveillance, but this has not been validated in controlled human trials. Cancer patients should not use DRC1 as an adjunct therapy without explicit oncologist guidance, as immune stimulation could interfere with certain immunotherapy protocols.

### What is the evidence for Lactococcus lactis DRC1 in wound healing?

Animal studies using topical or systemic DRC1 administration in wound models have produced mixed outcomes, with some murine studies suggesting accelerated granulation tissue formation and reduced Staphylococcus aureus colonization at wound sites, while high-dose administration in other models showed delayed healing, possibly due to excessive inflammatory cytokine release. The proposed mechanism involves TLR2-mediated macrophage activation promoting M1-to-M2 phenotype transition, which supports tissue remodeling. No human wound-healing trials for DRC1 specifically have been conducted, making clinical application premature.

### How is Lactococcus lactis DRC1 used in aquaculture and shrimp farming?

DRC1 has been studied as a probiotic feed additive in shrimp aquaculture, primarily targeting Vibrio harveyi and Vibrio parahaemolyticus infections, which are leading causes of mass mortality events in Penaeus species. In controlled Vibrio-challenge studies, shrimp fed DRC1-supplemented diets demonstrated improved survival rates compared to controls, attributed to competitive exclusion through lactic acid and BLIS production, alongside upregulation of prophenoloxidase cascade components in shrimp hemocytes. Typical experimental dosing in feed has ranged from 10^6 to 10^8 CFU per gram of feed, though optimal dosing protocols are not yet standardized.

### Is Lactococcus lactis biovar diacetylactis DRC1 safe to take as a supplement?

DRC1 belongs to a species (Lactococcus lactis) with a long history of safe use in food fermentation, which supports a general safety profile under typical food-equivalent exposure levels. However, as a defined probiotic supplement, no formal phase I or II human safety trials have been published specifically for the DRC1 strain, leaving the therapeutic dose range and adverse event profile undefined. Individuals with prosthetic heart valves, active gastrointestinal mucosal compromise, or severe immunosuppression should consult a physician before use, as rare but documented cases of Lactococcus bacteremia have been reported in highly vulnerable populations.

### What does the research evidence show about Lactococcus lactis DRC1's effectiveness compared to other probiotic strains?

Clinical evidence for Lactococcus lactis DRC1 remains limited, with most data derived from preliminary observations and animal studies rather than large-scale human trials. The strain shows promise in specific applications like aquaculture disease resistance (79.2% survival in challenge studies) and potential immune modulation, but direct head-to-head comparisons with other well-established probiotic strains in humans are lacking. Current evidence quality is considered preliminary, meaning more rigorous clinical trials are needed before making definitive claims about superiority over other probiotics.

### Who would benefit most from taking Lactococcus lactis DRC1 as a supplement?

Individuals interested in microbiota modulation and digestive enzyme enhancement may be potential candidates, though clinical evidence remains limited to specific populations. Those undergoing cancer therapy exploring complementary immune support options have been subjects of preliminary research, though this application requires medical supervision and should not replace conventional treatment. Persons seeking general digestive health support based on the strain's documented ability to influence microbiota composition may also consider supplementation, pending consultation with a healthcare provider.

### Are there specific populations who should avoid Lactococcus lactis DRC1 supplementation?

Immunocompromised individuals, including those with severe immunosuppression or critical illness, should consult healthcare providers before use, as live probiotic strains carry theoretical risks in these populations. People with lactose intolerance related to Lactococcus species fermentation should exercise caution, though DRC1's role in diacetyl production may differ from standard lactis strains. Those taking specific antimicrobial medications that target lactic acid bacteria should discuss timing and compatibility with healthcare providers to ensure the supplement remains viable.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*